Mounjaro and Atorvastatin Interaction: What Patients and Prescribers Need to Know

Does Mounjaro interact with atorvastatin?

Neither the Mounjaro prescribing information nor the Lipitor prescribing information names the other drug in its drug interaction sections [1][2].

Tirzepatide is a once-weekly subcutaneous injection that is metabolized by proteolytic cleavage and other non-CYP routes, and the label describes low in vitro potential to inhibit or induce CYP enzymes [1]. Atorvastatin is a CYP3A4 substrate and also a substrate of the transporters OATP1B1, OATP1B3 and BCRP; inhibitors of those pathways are what push its levels up [2].

The one tirzepatide effect that could touch any oral tablet is absorption timing: Mounjaro delays gastric emptying, and the label says this can affect the absorption of oral medicines taken with it [1].

What the Mounjaro label says about oral medicines

The label states that Mounjaro delays gastric emptying and has the potential to affect the absorption of oral medicines taken with it. It advises caution when oral drugs are given with Mounjaro, and monitoring of oral medicines that depend on threshold concentrations for efficacy or have a narrow therapeutic index, naming warfarin as an example [1]. The same section carries the oral contraceptive instruction: switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation [1].

Atorvastatin does not appear in that section, and the label gives no atorvastatin-specific dose instruction [1].

How large is the absorption effect, and how long does it last?

The tirzepatide label's measured numbers come from acetaminophen and an oral contraceptive, not from atorvastatin.

After a first 5 mg dose, acetaminophen peak concentration fell 55% and peak time came 1 hour later. By week 6, on 15 mg weekly, there was no meaningful effect on acetaminophen peak concentration or peak time, and total exposure (AUC) was unchanged [1].

With a combined oral contraceptive (0.035 mg ethinyl estradiol and 0.25 mg norgestimate) given alongside a single 5 mg dose, the peak concentration of ethinyl estradiol, norgestimate and norelgestromin fell 59%, 66% and 55%, total exposure fell 20%, 21% and 23%, and peak time was delayed 2.5 to 4.5 hours [1]. The label says the gastric emptying delay is largest after the first dose and diminishes over time [1].

What raises atorvastatin levels, and where does tirzepatide fit?

The interactions that matter for atorvastatin are drugs that inhibit CYP3A4 or its transporters. Clarithromycin 500 mg twice daily raised atorvastatin 80 mg AUC 4.54-fold, and itraconazole 200 mg daily raised a single 40 mg dose 3.32-fold; the Lipitor label says not to exceed atorvastatin 20 mg daily with either drug [2]. Cyclosporine raised atorvastatin 10 mg AUC 8.69-fold and the label says the combination is not recommended; gemfibrozil raised the AUC of a single 40 mg dose 1.35-fold and is also not recommended [2]. The label also advises avoiding large quantities of grapefruit juice, more than 1.2 liters daily [2].

Tirzepatide is not among the drugs the Lipitor label lists as raising atorvastatin exposure [2].

Does atorvastatin need to move to a different time of day?

The Mounjaro label says the injection can be given at any time of day, with or without meals [1]. The Lipitor label says the tablet can be taken at any time of day, with or without food, and notes that evening dosing gives about 30% lower atorvastatin concentrations than morning dosing while LDL-C reduction is the same at any time of day [2]. Neither label asks for the two to be separated.

Muscle symptoms

The Lipitor label lists myopathy and rhabdomyolysis as the main muscle risk, with risk factors of age 65 or older, uncontrolled hypothyroidism, renal impairment, interacting drugs and higher doses. It instructs patients to promptly report unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever, and describes rare immune-mediated necrotizing myopathy [2].

The Mounjaro label's warnings cover acute pancreatitis, acute gallbladder disease, kidney injury from volume depletion, hypoglycemia with insulin or sulfonylureas, diabetic retinopathy progression and pulmonary aspiration during anesthesia or deep sedation; muscle injury is not among them [1].

Blood sugar

The Mounjaro label's hypoglycemia warning concerns insulin and insulin secretagogues such as sulfonylureas, and the label says to consider reducing the dose of those drugs when Mounjaro is started [1]. Atorvastatin is neither. The Lipitor label notes that increases in HbA1c and fasting glucose have been reported with statins, including Lipitor [2]. In the SPARCL trial, diabetes was reported as an adverse reaction in 6.1% of patients on atorvastatin 80 mg versus 3.8% on placebo [2].